From GlobeNewswire: 2025-05-08 11:01:00

Genmab’s first quarter of 2025 saw a revenue increase of 19% compared to the same period in 2024, reaching $715 million. Key highlights included the approval of EPKINLY for additional indications by the Japan Ministry of Health, Labour, and Welfare, and Tivdak being approved by both Japan and the European Commission for treating recurrent or metastatic cervical cancer. Additionally, Rinatabart sesutecan continues to show promise in treating advanced ovarian cancer. The company’s CEO, Jan van de Winkel, emphasized the progress made with these late-stage programs. Total costs and operating expenses for the first quarter of 2025 were $527 million, with an operating profit of $188 million. Genmab’s 2025 financial guidance remains unchanged from earlier in the year. The company has updated its functional and presentation currency to USD, effective January 1, 2025. Forward-looking statements in the report caution of potential risks associated with product development, clinical trials, market acceptance, and competition. For more details, the full report is available on Genmab’s investor relations website.



Read more at GlobeNewswire:: Genmab Announces Financial Results for the First Quarter of